The manufacturers warn that
bupropion may raise
flecainide levels (by inhibiting CYP2D6). This seems a reasonable prediction as other CYP2D6 substrates are affected in this way.
If
flecainide is added to treatment with bupropion, doses at the lower end of the range should be used. If
bupropion is added to existing treatment, decreased dosages should be considered.